AstraZeneca Beats Q3 Forecasts and Shifts Focus to US Market

AstraZeneca reported third-quarter 2025 financial results on November 6 that exceeded revenue and core earnings forecasts. The company generated $15.19 billion in quarterly revenue, a 12% year-over-year increase, while net profit jumped 77% to $2.53 billion. Growth was primarily driven by oncology and respiratory and immunology segments, with 16 positive phase III trials announced during the year. Following the report, the company's shares reached a new all-time high.

Chief Executive Pascal Soriot announced a strategic pivot toward the United States, featuring a $50 billion investment in US manufacturing and research by 2030 and plans for a direct listing on the New York Stock Exchange. Soriot also detailed a "historic agreement" with the US government to lower medicine costs for American patients in exchange for a three-year delay on new tariffs. Chief Finance Officer Aradhana Sarin stated the company could absorb the financial impact of the pricing deal.

Despite the strong performance, the company maintained its full-year 2025 guidance, citing generic competition and a 9% rise in core operating expenses. Soriot warned that Europe could lose its health sovereignty if governments fail to provide more pharmaceutical industry support. Total revenue for the first nine months of 2025 reached $43.24 billion.